Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$7.31 -4.1%	$6.59	$4.64 ▼ $61.90	$89.45M	3.19	356,650 shs	94,402 shs
CRVS Corvus Pharmaceuticals	$3.80	$3.40	$1.75 ▼ $10.00	$259.04M	0.67	736,845 shs	509,024 shs
ORGS Orgenesis	$1.94 -0.5%	$2.25	$0.87 ▼ $10.80	$9.31M	0.72	9,322 shs	360 shs
TXMD TherapeuticsMD	$1.45 -2.0%	$1.21	$0.70 ▼ $2.44	$16.78M	0.5	156,848 shs	30,532 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	0.00%	-1.22%	-2.79%	-3.18%	-83.20%
CRVS Corvus Pharmaceuticals	0.00%	+8.88%	+7.95%	-5.94%	+80.95%
ORGS Orgenesis	0.00%	+2.11%	-12.32%	-49.48%	+193,999,900.00%
TXMD TherapeuticsMD	0.00%	0.00%	+4.32%	+55.91%	-33.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBP Corbus Pharmaceuticals	4.22 of 5 stars	4.6	0.0	0.0	4.7	3.8	1.7	0.0
CRVS Corvus Pharmaceuticals	2.1745 of 5 stars	3.5	1.0	0.0	0.0	2.3	2.5	0.6
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	1.6385 of 5 stars	0.0	5.0	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	595.96% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	294.74% Upside
ORGS Orgenesis	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRVS, CRBP, ORGS, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
3/26/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $15.00
3/26/2025	CRVS Corvus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/12/2025	CRBP Corbus Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$51.00
3/12/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $50.00
3/11/2025	CRBP Corbus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $53.00

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	($1.56) per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
ORGS Orgenesis	$662K	14.06	N/A	N/A	($6.58) per share	-0.29
TXMD TherapeuticsMD	$1.84M	9.12	N/A	N/A	$2.77 per share	0.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$44.60M	-$4.22	N/A	N/A	N/A	N/A	-42.28%	-32.92%	8/5/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/12/2025 (Estimated)
ORGS Orgenesis	-$55.36M	N/A	0.00	∞	N/A	-3,827.81%	N/A	-130.18%	8/6/2025 (Estimated)
TXMD TherapeuticsMD	-$10.28M	N/A	0.00	∞	N/A	-207.77%	-14.08%	-9.61%	8/11/2025 (Estimated)

Latest CRVS, CRBP, ORGS, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	TXMD TherapeuticsMD	N/A	-$0.06	N/A	-$0.06	N/A	$0.39 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/11/2025	Q4 2024	CRBP Corbus Pharmaceuticals	-$1.02	-$0.78	+$0.24	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	13.84	13.84
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
ORGS Orgenesis	N/A	0.07	0.07
TXMD TherapeuticsMD	N/A	2.03	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
CRVS Corvus Pharmaceuticals	46.64%
ORGS Orgenesis	22.56%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	4.00%
CRVS Corvus Pharmaceuticals	31.30%
ORGS Orgenesis	5.66%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.69 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
ORGS Orgenesis	150	4.80 million	4.53 million	No Data
TXMD TherapeuticsMD	420	11.57 million	11.27 million	Optionable

CRVS, CRBP, ORGS, and TXMD Headlines

Recent News About These Companies

StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

May 22, 2025 | americanbankingnews.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.com

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.com

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 15, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 15, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

TherapeuticsMD Inc. stock remains steady Wednesday, underperforms market

November 6, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains

October 22, 2024 | marketwatch.com

TherapeuticsMD Inc. stock remains steady Thursday, underperforms market

October 17, 2024 | marketwatch.com

TherapeuticsMD Inc. stock remains steady Friday, underperforms market

October 11, 2024 | marketwatch.com

TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market

October 11, 2024 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CRBP, ORGS, and TXMD Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$7.31 -0.31 (-4.07%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$7.18 -0.14 (-1.85%)

As of 05/30/2025 06:02 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$3.80 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.79 -0.01 (-0.26%)

As of 05/30/2025 06:18 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Orgenesis NASDAQ:ORGS

$1.94 -0.01 (-0.51%)

As of 05/30/2025 10:30 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

TherapeuticsMD NASDAQ:TXMD

$1.45 -0.03 (-2.03%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.44 -0.01 (-0.69%)

As of 05/30/2025 07:43 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time